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We report on markedly different frequencies of genetic lesions with-in subsets of chronic lymphocytic leukemia patients carryingmutated or unmutated stereotyped B-cell receptor immunoglobu-
lins in the largest cohort (n=565) studied for this purpose. By combining
data on recurrent gene mutations (BIRC3, MYD88, NOTCH1, SF3B1 and
TP53) and cytogenetic aberrations, we reveal a subset-biased acquisition of
gene mutations. More specifically, the frequency of NOTCH1 mutations
was found to be enriched in subsets expressing unmutated immunoglobu-
lin genes, i.e. #1, #6, #8 and #59 (22-34%), often in association with trisomy
12, and was significantly different (P<0.001) to the frequency observed in
subset #2 (4%, aggressive disease, variable somatic hypermutation status)
and subset #4 (1%, indolent disease, mutated immunoglobulin genes).
Interestingly, subsets harboring a high frequency of NOTCH1 mutations
were found to carry few (if any) SF3B1 mutations. This starkly contrasts
with subsets #2 and #3 where, despite their immunogenetic differences,
SF3B1mutations occurred in 45% and 46% of cases, respectively. In addi-
tion, mutations within TP53, whilst enriched in subset #1 (16%), were rare
in subsets #2 and #8 (both 2%), despite all being clinically aggressive. All
subsets were negative for MYD88 mutations, whereas BIRC3 mutations
were infrequent. Collectively, this striking bias and skewed distribution of
mutations and cytogenetic aberrations within specific chronic lymphocytic
leukemia subsets implies that the mechanisms underlying clinical aggres-
siveness are not uniform, but rather support the existence of distinct genetic
pathways of clonal evolution governed by a particular stereotyped B-cell
receptor selecting a certain molecular lesion(s).   
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ABSTRACT
Introduction
Immunogenetic studies have been instrumental in
revealing that the ontogeny of chronic lymphocytic
leukemia (CLL) is not stochastic, but rather antigen-dri-
ven, through the discovery that: (i) the immunoglobulin
(IG) gene repertoire of the clonotypic B-cell receptor (BcR)
displays restriction and, (ii) the level of somatic hypermu-
tations (SHM) present in rearranged IG heavy chain genes
defines two disease subtypes, each associated with a dif-
ferent clinical course.1-5 Such studies led to the discovery of
quasi-identical or stereotyped BcR IGs in more than 30%
of CLL patients who can be assigned to distinct subsets,
each defined by a particular BcR immunogenetic motif.6-14
Importantly, from both a biological and clinical perspec-
tive, evidence suggests that this classification of CLL based
on BcR stereotypy is highly relevant and extends well
beyond the SHM status of the BcR IG, thereby enabling
the identification of homogeneous disease subgroups and,
hence, overcoming the heterogeneity characteristic of
CLL.
Indeed, studies indicate that patients with similar SHM
status but assigned to different stereotyped subsets can
exhibit distinct, subset-biased biological profiles and clin-
ical behavior.10,15-25 In addition, preliminary observations
in CLL, in relatively small patient series, suggest that the
frequency and patterns of mutations within several genes,
namely, NOTCH1, SF3B1 and TP53, may differ amongst
subsets of patients carrying stereotyped BcRs, the para-
digmatic example being the recently observed enrich-
ment of SF3B1 mutations in the clinically aggressive sub-
set #2.26-28 
With this in mind, we sought to systematically evaluate
the mutational status of BIRC3, MYD88, NOTCH1,
SF3B1 and TP53 in 565 CLL patients assigned to one of 10
major stereotyped subsets, and representing cases with
varying SHM status, i.e. cases harboring either unmutated
IGHV genes (U-CLL) or mutated IGHV genes (M-CLL).
We demonstrate markedly different frequencies and spec-
tra of genomic defects amongst the various subsets. On
these grounds, we speculate that common genetic aberra-
tions, acquired and/or selected in the context of shared
immune pathways originating from highly similar BcR
IGs could shape the evolutionary pathway of individual
CLL subsets.
Methods
Patients
A total of 565 CLL patients, selected based on the expression of
stereotyped BcR IGs leading to their assignment to a major
subset,10,14 were included in this study (Table 1). A minimum
requirement was that data be available for at least 10 cases/subsets
to enable meaningful comparisons; this criterion resulted in 10
major subsets being evaluated. All cases were diagnosed according
to the 2008 IWCLL criteria.29 Informed consent was collected
according to the Declaration of Helsinki, and ethical approval was
granted by local review committees.
Cytogenetic and SNP-array studies
Interphase fluorescence in situ hybridization (FISH) for the
13q14, 13q34, 11q22, 17p13 chromosomal regions and the cen-
tromere of chromosome 12 was performed as previously
described.30 For 30 cases recurrent genomic aberration data was
obtained using the Affymetrix 250K SNP Array.31 
Sequence analysis of IGHV–IGHD–IGHJ rearrangements
PCR amplification, sequence analysis and interpretation of
IGHV-IGHD-IGHJ rearrangements were performed following
established international guidelines and using the IMGT® data-
base and the IMGT/V-QUEST tool, as previously reported.2,7,8,10
Clonotypic IGHV gene sequences were defined as either mutated
or unmutated based on the clinically relevant 98% cutoff value for
identity to the closest germline gene.4,5
Assignment of cases to specific stereotyped subsets was per-
formed following established guidelines and based on the follow-
ing stringent criteria: the IG sequences must: (i) have ≥ 50% amino
acid identity and 70% similarity within the variable heavy com-
plementarity-determining region 3 (VH CDR3); (ii) have the same
VH CDR3 length and the shared amino acid patterns must occur
at identical codon positions; and (iii) utilize IGHV genes belonging
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Table 1. Immunogenetic characteristics of the major stereotyped subsets analyzed in the present study.
Subset IG Mutational Subset size Cases IGHV IGHJ VH CDR3 VH CDR3 pattern
status* (%)† analyzed (N) gene(s) gene(s) AA length
#1 unmutated 2.4 137 Clan I genes IGHJ4 13 ARx[NQ]W[AVLI]xxxxFDx
#2 variable 2.8 162 IGHV3-21 IGHJ6 9 [AVLI]x[DE]xxxM[DE]x
#3 unmutated 0.6 26 IGHV1-69 IGHJ6 22 Axxxxx[AVLI][AVLI]VxxAxxxxYYGMDx
#4 mutated 1.0 78 IGHV4-34 IGHJ6 20 [AVLI]RGxxxxxxx[KRH]RYYYYGx[DE]x
#5 unmutated 0.7 25 IGHV1-69 IGHJ6 20 ARxxxxxx[AVLI]xxxYYYYxMDx
#6 unmutated 0.9 46 IGHV1-69 IGHJ3 21 ARGGxYDY[AVLI]WGSYRxx[DE][AVLI]FDx
#7 unmutated 0.3 12 IGHV1-69 IGHJ6 24 AxxxxxxDFW[ST]GYxxxxYYYxxDx
#8 unmutated 0.5 43 IGHV4-39 IGHJ5 18-19 AxxxxYSSSWxxxxNWFDP
#59 unmutated 0.3 18 Clan I genes variable 12 AxxxDFWSGxxx
#99 unmutated 0.3 18 Clan I genes IGHJ4 14 ARxQWLxxxxxFDx
Total 9.8 565
IG: immunoglobulin; IGHV: immunoglobulin heavy variable; IGHJ: immunoglobulin heavy joining; VH CDR3: heavy variable complementarity determining region 3; AA: amino acid.
*Cases with ≥98% identity to the germline were classed as unmutated (U-CLL), whereas cases with <98% germline identity were considered mutated (M-CLL). Subset #2 is com-
prised of both U-CLL and M-CLL. †Subset size refers to their approximate proportion within all CLL.14
to the same phylogenetic clan.13,14 The sole exception to these rules
concerned subset #8, where the specific combination of IGHV4-
39, IGHD6-13 and IGHJ5 genes resulted in a VH CDR3 motif that
was shared by two subgroups of cases bearing VH CDR3s that dif-
fered in length by a single amino acid residue (18 and 19 amino
acids) (Online Supplementary Table S1).10,14 For the present study,
these two ‘sub-subsets’ were considered as a single entity. The
immunogenetic characteristics of the subsets analyzed are provid-
ed in Table 1.
Gene mutation analysis
The date of the sample used for mutational analysis as well as
the date of the first treatment was available for >80% of patients,
and >80% of patients were tested prior to treatment (Online
Supplementary Table S2). Mutational screening was performed for
the following genes: NOTCH1, the entire exon 34 or targeted
analysis for del7544_7545/p.P2514Rfs*4; TP53, exons 4-10
(depending on the medical center); SF3B1, exons 14-16; BIRC3,
exons 6-9; and MYD88, exons 3 and 5 or targeted analysis for the
p.L265P substitution (exon 5). Specific methodologies are detailed
in the Online Supplementary Table S3.
Statistical analysis
Due to the complete absence or rarity of mutations in MYD88
and BIRC3, respectively, statistical analysis was only performed
for NOTCH1, SF3B1 and TP53 gene mutations. Pearson’s Chi-
squared test was used to evaluate the null hypothesis that the fre-
quency of mutations within each of the aforementioned genes is
equal among all subsets analyzed; the P value was computed by
Monte Carlo simulation with 10 000 replicates. Comparisons
between subsets were performed using the Fisher’s exact test and
all tests were two-sided. P values were corrected for multiple com-
parisons using the Bonferroni method and the level of significance
was set at P<0.001 (Online Supplementary Table S4). All calculations
were performed using R (version 3.1.2). 
Overall survival (OS) and time to first treatment (TTFT) were
measured from the date of diagnosis until last follow-up/death, or
date of initial treatment, respectively. Survival curves were con-
structed according to the Kaplan-Meier method, using Statistica
Software 10.0 (Stat Soft Inc., Tulsa, OK, USA), and the log-rank
test was used to determine the differences between survival pro-
portions. 
Results
Markedly different frequencies of genetic lesions
amongst stereotyped CLL subsets 
To investigate the associations between recurrent genet-
ic lesions in CLL and BcR IG stereotypy, we profiled 565
patients assigned to one of 10 major stereotyped subsets
(Table 1).10,14 Subset #4 cases (n=78) carried uniformly
mutated BcR IGs (M-CLL), whereas subset #2 cases
(n=162) exhibited significant heterogeneity with regard to
SHM load, leading to 98 cases being considered as M-CLL
and the remainder (n=64) as U-CLL (range: 93.3-99.7%;
median: 97.8%). All remaining subsets concerned cases
with unmutated or minimally mutated BcR IGs, hence
constituting U-CLL. Mutational analysis for all 5 genes,
BIRC3, MYD88, NOTCH1, SF3B1 and TP53, was per-
formed for 520/565 (92%) cases; mutation data for one or
two genes was lacking for 37 (6.5%) and 8 (1.5%) cases,
respectively (Online Supplementary Table S5). For compari-
son purposes, data concerning the frequency of recurrent
gene mutations and genetic lesions within non-stereo-
typed CLL is also provided in Table 2 and Online
Supplementary Table S6.
MYD88 mutations
All cases analyzed (n=557) were devoid of MYD88
mutations, which, bearing in mind that our cohort was
predominantly composed of U-CLL, was not surprising,
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Figure 1. Recurrent gene mutations in stereotyped CLL subsets. The distribution of mutations within NOTCH1, SF3B1 and TP53 varied considerably between the
major stereotyped subsets included in the present study. All cases were devoid of MYD88 mutations and BIRC3 mutations were rare, with no clear bias to any subset
(this data is not shown in the graph). M-CLL: mutated IGHV gene; U-CLL: unmutated IGHV gene.
since existing evidence indicates that MYD88 mutations
exclusively occur in M-CLL.32-37 That said, 32% (176/557)
of cases analyzed concerned M-CLL, subset #2 (n=98)
(mixed SHM profile) and subset #4 (n=78), and the com-
plete absence of MYD88 mutations amongst these cases
implies that mutations within MYD88 are absent from 
M-CLL assigned to major stereotyped subsets.
BIRC3 mutations
Mutations within BIRC3 were infrequent (7/541 cases,
1.3%) and primarily concerned truncating mutations i.e.
small frameshift deletions, duplications or insertions, as
opposed to single nucleotide variants (Table 2; Online
Supplementary Tables S6 and S7). BIRC3-mutated cases
lacked del(17p), however a single subset #1 case did coex-
ist with a TP53mutation within the DNA-binding domain
(Online Supplementary Table S7); the remaining cases har-
bored del(11q) (n=1), trisomy 12 (n=3) or both del(11q)
and trisomy 12 (n=2). Five out of 7 (71%) BIRC3-mutant
cases carried mutations within one of the other genes ana-
lyzed; 4/5 cases had concurrent mutations within
NOTCH1. Irrespective of subset assignment, BIRC3muta-
tions never coincided with SF3B1 mutations (Online
Supplementary Table S7). 
NOTCH1 mutations
Mutations within exon 34 of the NOTCH1 gene were
detected in 15% (82/563) of cases. The frequency of
NOTCH1 mutations varied considerably among subsets
and can be summarized as follows: (i) subsets #1, #59 and
#99, all concerning U-CLL, exhibited high frequencies of
NOTCH1 mutations (22%, 30% and 33%, respectively);
(ii) NOTCH1 mutations were also enriched in subset #6
(22%), but relatively infrequent in subsets #3, #5 and #7
(4%, 8% and 8%, respectively), despite the fact that all
these subsets utilize the IGHV1-69 gene and concern U-
CLL; (iii) NOTCH1 mutations were prevalent in the clini-
cally aggressive subset #8 (IGHV4-39/IGKV1(D)-39), rang-
ing from 21-34% depending on the VH CDR3 length and
18 or 19 amino acids, respectively; (iv) aberrations within
NOTCH1were uncommon in subset #2, which comprises
both U- and M-CLL, being present in only 4% of analyzed
cases (7/162; 5/7 (71%) NOTCH1-mutant subset #2 cases
concerned M-CLL while the remaining 2 cases were U-
CLL); and, finally, (v) defects within NOTCH1were rare in
subset #4 (1/78; 1.3%) (Figure 1; Table 2; Online
Supplementary Tables S1 and S6). To account for multiple
testing, Bonferroni correction was performed and pairwise
comparisons between subsets was checked at a level of
significance of P<0.001, indicating that the frequencies of
NOTCH1mutations in subsets #2 and #4 were statistically
significant compared to the frequencies observed in sub-
sets #1, #6, #8 and #59 (Online Supplementary Table S4A).
Although significance was not reached for other subset
comparisons, this could in part be explained by the small
number of cases included within each of these subsets,
thus underscoring an inherent limitation when analyzing
stereotyped subsets due to the fact that even the largest
subsets account for less than 5% of all CLL cases.
Although NOTCH1 mutations tended to coincide with
trisomy 12, their co-occurrence differed among subsets
(Table 2; Online Supplementary Table S6). Concurrent muta-
tions were uncommon in NOTCH1-mutated cases, with
the vast majority (79%; 65/82) devoid of mutations in the
other four genes included in the study. The combinatorial
patterns of mutations occurring in the remaining 21% of
cases (17/82) were as follows: (i) NOTCH1 and TP53
mutations coexisted in 7/17 (41%) cases comprising sub-
set #1 (n=4), subset #99 (n=2) and subset #6 (n=1); (ii)
mutations in NOTCH1 and either SF3B1 or BIRC3
occurred at similar frequencies, 5/17 (29%) and 4/17
(24%), respectively, with no bias to any particular subset;
and (iii) a single subset #1 case carried mutations in
NOTCH1, TP53 and SF3B1. Notably, subsets harboring
NOTCH1 mutations at high frequencies were either
absent for (subsets #8 and #99) or concerned a single case
with a co-occurring SF3B1 mutation (subsets #1, #6 and
#59).
SF3B1 mutations
Mutations within the SF3B1 gene (hotspot exons 14-16)
were detected in 19% (106/564) of cases. A very high fre-
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Table 2. Frequency of recurrent mutations and cytogenetic aberrations within each subset included in the present study. 
#1 (n=137) #99 (n=18) #59 (n=18) #3 (n=26) #5 (n=25) #6 (n=46) #7 (n=12) #8 (n=43) #2 (n=162) #4 (n=78) n=289
Immunogenetics UM Clan I genes UM IGHV1-69 UM M & UM M Heterogeneous
IGHV4-39 IGHV3-21 IGHV4-34 CLL
Mutations
NOTCH1mut 37/137 (27%) 4/18 (22%) 6/18 (33%) 1/26 (4%) 2/24 (8%) 10/45 (22%) 1/12 (8%) 13/43 (30%) 7/162 (4%) 1/78 (1%) 10/280 (3.6%)
TP53mut 21/135 (16%) 6/18 (33%) 0/18 (0%) 2/25 (8%) 0/25 (0%) 2/45 (4%) 1/10 (10%) 1/43 (2%) 3/150 (2%) 3/78 (4%) 11/237 (4.6%)
SF3B1mut 9/137 (7%) 0/18 (0%) 2/18 (11%) 12/26 (46%) 2/25 (8%) 6/46 (13%) 3/12 (25%) 0/43 (0%) 72/161 (45%) 0/78 (0%) 10/280 (3.6%)
BIRC3mut 2/131 (2%) 0/17 (0%) 0/18 (0%) 0/25 (0%) 1/21 (5%) 0/45 (0%) 1/12 (8%) 3/42 (7%) 0/153 (0%) 0/77 (0%) 0/189 (0%)
MYD88mut 0/135 (0%) 0/18 (0%) 0/18 (0%) 0/25 (0%) 0/24 (0%) 0/45 (0%) 0/12 (0%) 0/42 (0%) 0/159 (0%) 0/78 (0%) 5/206 (2.4%)†
Genetic aberrations
del(17p) 12/100 (12%) 2/13 (15%) 0/12 (0%) 2/18 (11%) 0/20 (0%) 2/34 (6%) 3/9 (33%) 3/23 (13%) 0/128 (0%) 0/59 (0%) 10/269 (3.7%)
del(11q) 22/98 (22%) 2/13 (15%) 1/12 (8%) 7/19 (37%) 8/21 (38%) 5/34 (15%) 1/9 (11%) 3/22 (14%) 30/126 (24%) 3/59 (5.1%) 29/269 (11%)
trisomy 12 14/90 (16%) 3/12 (25%) 8/10 (80%) 1/17 (6%) 3/18 (17%) 3/34 (9%) 2/8 (25%) 13/20 (65%) 5/124 (4%) 1/52 (2%) 29/269 (11%)
del(13q)* 18/89 (20%) 3/12 (25%) 1/10 (10%) 3/17 (18%) 5/17 (29%) 9/34 (26%) 2/8 (25%) 1/20 (5%) 67/123 (54%) 28/52 (54%) 135/269 (50%)
no RCAs 30/89 (34%) 2/12 (17%) 0/10 (0%) 6/17 (35%) 5/17 (29%)16/34 (47%) 1/8 (13%) 3/20 (15%) 26/123 (21%) 20/52 (38%) 72/269 (27%)
*refers to del(13q) as the sole aberration. RCAs: recurrent cytogenetic aberrations; †one MYD88-mutant case also carried a mutation within TP53. NOTCH1mut: mutation in NOTCH1; TP53mut:
mutation in TP53; SF3B1mut: mutation in SF3B1; BIRC3mut: mutation in BIRC3; MYD88mut: mutation in MYD88; UM: cases with unmutated IGHV genes; M: cases with mutated IGHV genes. The
‘Heterogeneous CLL’ cases described in the last column of this table refers to newly diagnosed CLL patients from a population-based cohort called SCALE (Scandinavian Lymphoma Etiology).
Within this study, 330 CLL cases had immunogenetic and mutation data available, resulting in 41 cases (12%) carrying stereotyped BcR IGs and therefore being assigned to a major subset.
For comparison purposes, the frequency of recurrent mutations and cytogenetic aberrations in the remaining cases carrying heterogeneous BcR IGs (n=289) are provided.32
quency of SF3B1mutations was not only observed in sub-
set #2 (45%; 72/161) but also in subset #3 (46%; 12/26),
which collectively accounted for 79% (84/106) of all
SF3B1 mutated cases. The frequency of SF3B1 mutations
in both subsets #2 and #3 sharply contrasted the frequency
observed in all other subsets, and reached statistical signif-
icance when compared to subsets #1, #4, #8 and #99
(P<0.001, the frequency of SF3B1 mutations in subset #2
also reached significance when compared to subsets #5
and #6) (Figure 1; Table 2; Online Supplementary Tables S4B,
S6 and S8). No significant difference in the distribution of
SF3B1mutations was observed between subset #2 M-CLL
cases (47/98; 48%) versus subset #2 U-CLL cases (25/64;
39%) (P=0.27).  
The SF3B1 mutation distribution within subset #2 was
remarkably skewed, with 77% (58/75; 3 subset #2 cases
carried 2 SF3B1 mutations) of mutations localized to two
codons (p.K700E: n=43/75, 57%; p.G742D: n=15/75,
20%; Figure 2A; Online Supplementary Table S8). Similar to
subset #2, the p.K700E substitution accounted for a high
proportion of SF3B1 mutations in subset #3 (33%; 4/12),
while the p.G742D mutation was absent (Figure 2A;
Online Supplementary Table S8). 
When considering cytogenetic aberrations, subset #2
was enriched for del(11q) (30/126; 24%) and isolated
del(13q) (67/123; 54%), in line with previous reports.16,23,38
SF3B1-mutated subset #2 cases showed a negative associ-
ation with isolated del(13q) (25/57 vs. 42/66; P=0.028).
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Figure 2. SF3B1 mutations in subsets #2 and #3. (A) Distribution of SF3B1 mutations in subsets #2 and #3. Overall, 45% (72/161) of subset #2 and 46% (12/26)
of subset #3 cases were found to carry mutations within SF3B1. While the majority of subset #2 cases (69/72; 96%) carried a single SF3B1 mutation, 3 cases had
2 mutations within SF3B1 (2/3 cases carried the p.K700E change, with one case carrying both p.K700E and p.G742D). Although the most frequent amino acid
change in both subsets involved a lysine to glutamic acid substitution at codon 700 (exon 15), representing 57% (43/75) and 33% (4/12) of all SF3B1 mutations in
subsets #2 and #3, respectively, the overall distribution of mutations varied. To elaborate, in subset #3, all remaining SF3B1 mutations (excluding p.K700E) occur
within exon 14. This is in contrast to the SF3B1 mutational profile in subset #2 where only 17% of mutations are found within exon 14 and where two particular sub-
stitutions account for 96% and 88% of the alterations observed in exon 15 and exon 16 (p.K700E and p.G742D, respectively). *indicates that more than one amino
acid change occurred at this codon (detailed in Online Supplementary Table S8). (B) Prognostic implications of SF3B1 mutations within subset #2 on overall survival
(OS) and time to first treatment (TTFT). (Binet A cases).
A
B
Within subset #2 cases, del(11q) was associated with
shorter TTFT  (Online Supplementary Figure S1A), whereas
SF3B1 mutations had no significant impact on either OS
or TTFT (for Binet A patients) (Figure 2B; Online
Supplementary Figure S1B-S1F). Despite their immuno-
genetic differences, similar to subset #2, subset #3 was
also enriched for del(11q) (7/19; 37%), with both 
SF3B1-mutant and wild-type subset #3 cases carrying
del(11q) in similar proportions (Table 2). 
Finally, across all subsets, SF3B1 mutations tended to
occur in isolation, e.g. for SF3B1-mutant cases, 94%
(68/72) of subset #2, 75% (9/12) of subset #3 and 83%
(5/6) of subset #6 had no coincident mutations within any
other gene analyzed. The sole exception concerned subset
#1, within which 56% (5/9) of SF3B1-mutant cases coex-
isted with mutations in TP53 (one case also carried a
mutation within NOTCH1). 
TP53 mutations
Overall, the majority of cases analyzed had no muta-
tions within TP53 (93%; 508/547). That said, we noted
differences in the frequency of TP53 mutations amongst
specific subsets, ranging from 0% to 33% (Figure 1; Table
2; Online Supplementary Tables S4C, S6 and S9). In particu-
lar, we found that TP53 mutations were: (i) absent in sub-
set #59; (ii) rare in subsets #2 (3/150; 2%), #4 (3/78; 4%)
and #8 (1/43; 2%); (iii) had varying, albeit low, frequencies
in U-CLL subsets utilizing the IGHV1-69 gene (Subsets #3:
2/25 (8%); #5: 0/25 (0%); #6: 2/45 (4%) and #7: 1/10
(10%)); and (iv) were enriched in subsets #1 (21/135; 16%)
and #99 (6/18; 33%); the latter representing a less populat-
ed subset that immunogenetically bears a high similarity
to subset #1. The high frequency of TP53 mutations in
these latter two subsets reached statistical significance
compared to the frequency observed in subset #2 (Online
Supplementary Table S4C). Of note, when incorporating
del(17p) into our analysis, the frequency of TP53 aberrant
cases in subsets #1 and #99 increased to 22% and 40%,
respectively (Online Supplementary Table S9). Subsets #5
and #59 remained unaffected by any TP53 lesions, while
the number of cases inflicted with TP53 defects increased
to 3/8 (37.5%) for subset #7 and 4/19 (21%) for subset #3
(Online Supplementary Table S9). 
As mentioned above, a significant proportion of 
TP53-mutated cases carried concurrent mutations in other
genes analyzed. More specifically, almost 50% of 
TP53-mutant subset #1 cases were positive for either
SF3B1 or NOTCH1 mutations (both 4/21, 19%), whereas
one case was positive for all three mutations; an additional
case carried a mutation within BIRC3. Regarding subset
#99, 2/6 (33%) of TP53-mutant cases carried double muta-
tions, with both cases carrying the recurrent 2 base pair
deletion in NOTCH1. 
Discussion 
Within this study, by combining data concerning both
recurrent gene mutations and cytogenetic aberrations in
the largest series of stereotyped subset CLL cases studied
to date for this purpose, we were able to offer important
novel insights into the molecular mechanisms driving the
pathogenesis and evolution of each subset. Overall, we
document that the genetic makeup of individual stereo-
typed subsets is remarkably distinct, which alludes to the
subset-biased acquisition and/or selection of genetic aber-
rations likely in the context of particular BcR signaling ini-
tiated by the subset-specific IG. 
Beginning with U-CLL subsets, it is noteworthy that
even when comparing subsets with BcR IGs utilizing the
same IGHV gene, their genomic profiles are distinct, as
exemplified by the subsets utilizing IGHV1-69 (subsets #3,
#5, #6 and #7), which displayed markedly different spectra
of genomic aberrations. For instance, SF3B1 mutations
were detected in an impressive 46% of subset #3 cases ver-
sus only 8% of subset #5 cases. Similar observations
regarding the skewed distribution of particular recurrent
gene mutations were also apparent for NOTCH1 muta-
tions, which were detected at a much higher frequency in
subset #6 (22%) versus all other IGHV1-69 subsets (fre-
quencies 4-8%); interestingly, within subset #6, NOTCH1
mutations rarely co-occurred with trisomy 12. Finally,
TP53 defects due to mutations within TP53 and/or
del(17p) ranged from 37.5% in subset #7 to 0% in subset
#5. 
Switching our focus to U-CLL subsets #8 and #59, two
clinically aggressive subsets, with the former exhibiting
the highest risk for Richter's transformation amongst all
CLL,15 revealed a very high frequency of trisomy 12 (65%
and 80%, respectively) and an enrichment in NOTCH1
mutations (30% and 33%, respectively), with a relatively
low frequency or complete absence of all other genomic
aberrations evaluated.23 
A similarly skewed distribution of genomic aberrations
was identified for another very aggressive CLL subset,
subset #2, which is the largest subset overall.14,23 Indeed,
we herein confirm and significantly extend previous
observations that subset #2 is remarkably enriched for
mutations within the SF3B1 gene.26,27 Of note, the target-
ing profile of mutations in the hotspot regions of SF3B1
(exons 14-16) clearly differed in subset #2 from that in sub-
set #3. Although the actual significance of these observa-
tions is currently unknown, the high frequency and strik-
ing bias of SF3B1 mutations to subsets #2 and #3 bodes
strongly for their critical role in the pathobiology of these
subsets. Furthermore, it supports the argument that the
mechanisms underlying clinical aggressiveness in CLL are
not uniform, but rather differ among the various disease
subgroups. 
Along these lines, the relative paucity of TP53 defects in
subset #2 (2%) implies that the poor prognosis of subset
#2 is attributable to other factors, with SF3B1 seemingly
appearing as a top candidate. That said, when comparing
subset #2 cases with/without SF3B1 mutations, no differ-
ence in OS or TTFT (Binet A cases) were observed, sug-
gesting that SF3B1 dysregulation alone does not explain
the clinical aggressiveness of subset #2. Since SF3B1 gene
mutations are also found in other malignancies, most
notably myelodysplastic syndrome, within which their
presence appears to confer a more favorable prognosis,39 it
is conceivable that the functional impact of SF3B1 muta-
tions may be influenced by the specific microenvironment
and/or differ in distinct blood cell lineages, hence produc-
ing context-dependent effects. 
The discussion about aggressive CLL subsets culminates
with subset #1, the biggest within U-CLL and second
largest overall after subset #2.14 In contrast to the subsets
mentioned above, the pattern of cytogenetic aberrations
and recurrent gene mutations in subset #1 is quite hetero-
geneous (Figure 3A and 3B; Table 2). Of note, TP53 disrup-
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tion (due to del(17p) and/or TP53 mutations), NOTCH1
mutations and trisomy 12 were all frequent in subset #1
(22%, 27% and 16% of cases, respectively); although
lesions within both TP53 and NOTCH1 co-occurred in
only 5 cases, all were negative for trisomy 12. Altogether,
these findings support the existence of distinct genetic
pathways of clonal evolution in subset #1, one influenced
and dictated by TP53 disruption, while the other is
dependent on trisomy 12 and/or NOTCH1 mutations.
Regarding the latter, given the very recent discovery of
recurrent mutations in the 3’ UTR of NOTCH1 in approx-
imately 3% of CLL patients,40 it is plausible that their fre-
quency in both subset #1 and CLL at large has been under-
estimated to date, nevertheless, this does not detract from
the apparent non-random association of the p.P2514Rfs*4
NOTCH1 mutation reported herein with certain stereo-
typed CLL subsets.
We next integrated these findings with the specific
immunogenetic nature of subset #1, taking into consider-
ation the fact that cases assigned to this subset differ from
most major CLL subsets, in that they do not all express the
same IGHV gene but rather carry IGHV genes that share
common ancestry and thus, belong to the same IGHV
phylogenetic clan, clan I (comprising IGHV1, IGHV5 and
IGHV7 genes).10,14 Focusing on the IGHV1-2*02 and
IGHV1-3*01 genes, which accounted for 64% of all subset
#1 cases (28.7% and 35.3%, respectively), it was interest-
ing to note that 17/39 (43.6%) IGHV1-2*02 expressing
cases carried mutations within NOTCH1 compared to
only 7/48 (14.6%) IGHV1-3*01 expressing subset #1 cases
(P=0.003) (Figure 3C). This finding further exemplifies
how the expression of a particular stereotyped
immunoglobulin may be linked to a distinct evolutionary
pathway through the acquisition of specific genomic aber-
rations. Whether these genomic differences may translate
into different clinical outcomes remains to be elucidated. 
Another important observation relates to the finding
that approximately 20% of subset #1 cases were negative
for any of the genetic lesions tested for (mutations or aber-
rations). Thus, for at least a proportion of subset #1 cases,
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Figure 3. Main biological associations within subset #1. (A) Concurrent mutations within subset #1. Only cases for which the mutational status of all 3 genes
(NOTCH1, SF3B1 and TP53) was available were included in the figure (n=135). Fifty-seven cases had a mutation in at least one of the gene hotspots whereas 78
cases were wild-type for these genes. (B) Spectrum of mutations and genomic aberrations within subset #1. Despite a high frequency of NOTCH1 mutations, a large
proportion (58%) of subset #1 cases carried no mutations within the 5 genes analyzed. Specifically, considering the subset #1 cases lacking any recurrent gene
mutations, 35% also lacked any recurrent genetic aberrations. Collectively, this resulted in the absence of any recurrent gene mutation or cytogenetic aberration in
approximately 20% of subset #1 cases, thereby implying that additional mechanisms must account for the clinically aggressive nature of this subset. Only cases for
which the mutational status of all 3 genes (NOTCH1, SF3B1 and TP53) was available were included in the figure (n=135). *indicates that none of the known recur-
rent genomic aberrations were present; NOTCH1mut: mutation in NOTCH1 only; TP53mut: mutation in TP53 only; SF3B1mut: mutation in SF3B1 only. Concurrentmut refers
to the presence of mutations in more than one of the genes analyzed. Absolute numbers and percentages are provided in brackets. For del(17p), 2/53 correspond
to the 4% indicated in the figure. (C) The frequency of NOTCH1 mutations in subset #1 cases varies depending on specific IGHV gene usage. Only the top 3 utilized
IGHV genes within subset #1 patients in our cohort were included in the graph, collectively accounting for 73% (99/136) subset #1 cases. Mutations within NOTCH1
were found to be particularly frequent in subset #1 cases expressing IGHV1-2*02 (17/39; 44%).   
A
C
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it appears that the full extent of their genomic complexity
has yet to be revealed, and additional mechanisms must
underlie their clinical aggressiveness. This claim is sup-
ported by recent high-throughput studies which indicate
that mutations within the NFKBIE or RPS15 gene may
serve as novel pathogenic mechanisms linked to a more
aggressive disease.41,42 While highlighting an inherent limi-
tation of the present study, which was restricted to the
analysis of 5 recurrently mutated genes, these results,
together with the recent finding of non-coding recurrent
mutations in CLL, emphasize the need for more compre-
hensive approaches, such as whole-genome sequencing,
in order to obtain a complete picture of the genomic land-
scape of CLL subsets.40
Finally, we looked to subset #4, the largest subset within
M-CLL and now considered as a prototype for indolent
disease.14,23 Previous studies have reported that subset #4 is
virtually devoid of cytogenetic aberrations associated with
adverse prognosis [del(11q) and, especially, del(17p)].16
Herein, we not only confirm and significantly extend
these observations, but also take a decisive step further by
showing that subset #4 essentially lacks recurrent gene
mutations, at least amongst the five genes analyzed.
These results provide insights into the ‘mild’ genomic
background of subset #4 CLL, which is reflected in the
indolent clinical course experienced by these patients.
Although our understanding of the genetic basis, clonal
architecture and evolution in CLL pathogenesis is rapidly
advancing, the CLL cell of origin and the precise timeline
of events leading to leukemogenesis remain elusive. It has
recently been proposed that hematopoietic stem cells
(HSCs) may be involved in CLL pathogenesis, since they
have been shown to harbor mutations within potential
CLL oncogenes.43,44 These cells could undergo antigen-dri-
ven clonal selection and progressively acquire additional
genetic abnormalities giving rise to a clonal B cell expan-
sion, termed monoclonal B-cell lymphocytosis (MBL),
which we know invariably precedes CLL, and ultimately
may progress to CLL. However, in trying to reconcile the
above scenario with the biology of CLL, this model fails to
account for the fact that none of the recurrent CLL chro-
mosomal abnormalities were found in the HSC compart-
ment; how could such clones be selected and subsequent-
ly expand into CLL? In addition, CLL patients who
achieve remissions do not relapse with polyclonal disease
or distinct clones. Further studies are therefore required to
both confirm and clarify the precise role of HSCs in CLL
pathogenesis. 
A minute proportion of MBL transform to overt CLL
requiring treatment (1-2%/year), thus significant somatic
changes coupled with microenvironmental factors must
occur.45 The existence of stereotyped BcRs together with
the tendency of CLL cells to express poly- and auto-reac-
tive BcRs are indicative of selective pressures, such as
autoantigens or microbial pathogens, that favor specific IG
gene rearrangements. Such persistent stimulation through
the surface IG may be the central event that drives the
evolution from a preleukemic state to overt leukemia,
thereafter chronic BcR engagement may favor the selec-
tion of a monoclonal population which subsequently
acquires genetic alterations, which in some instances may
provide a survival and growth advantage.45
In conclusion, our present findings imply that distinctive
modes of microenvironmental interactions, mediated by
certain stereotyped BcRs, may be associated with the
selection or occurrence of particular genetic aberrations,
with the combined effect determining both clonal and
clinical evolution, and ultimately disease outcome. Our
study further serves to highlight the fact that even findings
within smaller subsets help to dissect the pathophysiology
of CLL, and may eventually have clinical usability akin to
the known prognostication value of TP53 gene mutations,
despite being present in only 5-10% of cases at diagnosis
or the association between subset #8 (0.6% of all CLL) and
Richter’s transformation.15,46 Overall, since the distinct
genomic profiles evidenced amongst stereotyped CLL
subsets are potentially linked to varying mechanisms of
clinical aggressiveness based on a reliance on specific
intracellular signaling pathways, our findings may have
important implications for patient monitoring and thera-
peutic management in the era of targeted pathway inhibi-
tion.
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